

Highlights

- RE-AKT is a multicentre, randomized, double-blinded phase II trial in mCRPC
- Combined capivasertib and enzalutamide did not increase enzalutamide's antitumour activity in mCRPC
- Albeit well tolerated, capivasertib exposure is reduced when enzalutamide is given